Krystal Biotech, Inc. (KRYS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
2100 Wharton Street
Pittsburgh, PA 15203
United States of America (the)
Phone
412 586 5830
Website
Sector
Healthcare
Industry
Biotechnology
Employees
275
First IPO Date
September 20, 2017
| Name | Title | Pay | Year Born |
| Krish S. Krishnan | Founder, Chairman, President & Chief Executive Officer | 1.66M | 1965 |
| Kathryn A. Romano | Executive Vice President & Chief Accounting Officer | 674,756 | 1982 |
| Suma Krishnan | Founder, President of R&D and Director | 1.11M | 1965 |
| John Thomas | EVP, General Counsel & Corporate Secretary | 0 | 1974 |
| John Karakkal | Vice President of North American Sales & Marketing | 0 | N/A |
| Josh Suskin | Senior Director & Head of US Human Resources | 0 | N/A |
| Laurent Goux | Executive VP & Head of International | 0 | 1975 |
| Christine Wilson | Senior VP & Head of US Commercial | 0 | N/A |
| David Chien | Senior Vice President of Clinical Development | 0 | N/A |
| Stephane Paquette | Senior Vice President of Corporate Development | 0 | N/A |
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.